Cytokinetics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 1997, the company focuses on the discovery and development of small molecule therapeutics that modulate muscle function. Leveraging its expertise in muscle biology and chemistry, Cytokinetics aims to address a range of diseases characterized by impaired muscle performance, including heart failure and neuromuscular disorders.
The company’s lead programs target both cardiac and skeletal muscle. Omecamtiv mecarbil, a cardiac myosin activator, is being developed for patients with chronic heart failure with reduced ejection fraction, while aficamten, a next-generation cardiac myosin inhibitor, is designed for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. In the neuromuscular space, reldesemtiv, a fast skeletal muscle troponin activator, is in clinical evaluation for conditions such as amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. Cytokinetics also pursues early-stage discovery programs to expand its pipeline into new therapeutic areas.
To advance its clinical programs and broaden its development capabilities, Cytokinetics has established strategic partnerships with global pharmaceutical companies. Collaborations with Astellas Pharma have supported the global development of aficamten, while agreements with Amgen have facilitated the advancement of cardiac muscle activators. Cytokinetics operates clinical trial sites across North America, Europe and Asia, working closely with regulatory authorities to support potential future approvals.
Leadership at Cytokinetics is headed by President and Chief Executive Officer Robert I. Blum, M.D., who brings extensive experience in cardiovascular drug development. Under Dr. Blum’s stewardship since 2016, the company has expanded its pipeline and strengthened its scientific platform. Supporting him is a management team of drug development and commercial veterans who drive Cytokinetics’ mission to deliver first-in-class muscle-directed therapies to patients worldwide.
AI Generated. May Contain Errors.
Free CYTK Stock Alerts